Panobinostat reduces hypoxia-induced cisplatin resistance of non-small cell lung carcinoma cells via HIF-1α destabilization

Molecular Cancer

Volumn 14, Issue 1, 2015, Pages

  Fischer, Carina ^a,b   Leithner, Katharina ^a   Wohlkoenig, Christoph ^a   Quehenberger, Franz ^a   Bertsch, Alexandra ^a   Olschewski, Andrea ^a   Olschewski, Horst ^a   Hrzenjak, Andelko ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b Red Cross Transfusion Service for Upper Austria   (Austria)

Author keywords

Apoptosis; Cisplatin; HIF 1 ; Non small cell lung cancer; Panobinostat

Indexed keywords

CASPASE 3; CASPASE 7; CISPLATIN; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 4; HYPOXIA INDUCIBLE FACTOR 1ALPHA; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PANOBINOSTAT; ANTINEOPLASTIC AGENT; HISTONE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; INDOLE DERIVATIVE;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CELL VIABILITY; CHROMATIN; CLINICAL ARTICLE; CONTROLLED STUDY; HISTONE ACETYLATION; HUMAN; HUMAN CELL; IN VITRO STUDY; NON SMALL CELL LUNG CANCER; PROTEIN ACETYLATION; PROTEIN DEGRADATION; PROTEIN EXPRESSION; ACETYLATION; ANOXIA; CELL PROLIFERATION; CELL SURVIVAL; DNA FRAGMENTATION; DRUG EFFECTS; DRUG POTENTIATION; DRUG RESISTANCE; EPITHELIUM CELL; GENE EXPRESSION; GENETICS; LUNG TUMOR; METABOLISM; MULTICELLULAR SPHEROID; TUMOR CELL CULTURE; TUMOR CELL LINE;

ACETYLATION; ANOXIA; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CISPLATIN; DNA FRAGMENTATION; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; EPITHELIAL CELLS; GENE EXPRESSION; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HISTONES; HUMANS; HYDROXAMIC ACIDS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; INDOLES; LUNG NEOPLASMS; SPHEROIDS, CELLULAR; TUMOR CELLS, CULTURED;

EID: 84924358140     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-14-4     Document Type: Article

References (52)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin2011, 61:69-90. 10.3322/caac.20107
2. Alberg AJ, Samet JM: Epidemiology of lung cancer. Chest2003, 123:21-49. 10.1378/chest.123.1_suppl.21S
3. Pao W, Wang TY, Riely GJ, Miller VA, Pan Q, Ladanyi M, et al.: KRAS mutations and primary resistance of lung adenocarcinomas to Gefitinib or Erlotinib. PLoS Med 2005, 2:57-61.
4. Miller VA, Kris MG, Shah N, Patel J, Azzoli C, Gomez J, et al.: Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol2004, 22:1103-1109. 10.1200/JCO.2004.08.158
5. Travis WD, Travis LB, Devesa SS: Lung cancer. Cancer1995, 75:191-202. 10.1002/1097-0142(19950101)75:1+<191::AID-CNCR2820751307>3.0.CO;2-Y
6. Pao W, Miller VA: Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. J Clin Oncol2005, 23:2556-2568. 10.1200/JCO.2005.07.799
7. Giaccone G: Clinical perspectives on platinum resistance. Drugs 2000, 59:9-17.
8. Chen D, Milacic V, Frezza M, Dou QP: Metal complexes, their cellular targets and potential for cancer therapy. Curr Pharm Des2009, 15:777-791. 10.2174/138161209787582183
9. Momekov G, Ferdinandov D, Bakalova A, Zaharieva M, Konstantinov S, Karaivanova M: In vitro toxicological evaluation of a dinuclear platinum(II) complex with acetate ligands. Arch Toxicol2006, 80:555-560. 10.1007/s00204-006-0078-0
10. Vaupel P, Mayer A: Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev2007, 26:225-239. 10.1007/s10555-007-9055-1
11. Shannon AM, Bouchier-Hayer DJ, Condron CM, Toomey D: Tumor hypoxia, chemotherapeutic resistance and hypoxia-related therapies. Cancer Treat Rev2003, 29:297-307. 10.1016/S0305-7372(03)00003-3
12. Mansfield KD, Simon MC, Keith B: Hypoxic reduction in cellular glutathione levels requires mitochondrial reactive oxygen species. J Appl Physiol2004, 97:1358-1366. 10.1152/japplphysiol.00449.2004
13. Song X, Liu X, Chi W, Liu Y, Wei L, Wang X, et al.: Hypoxia-induced resistance to cisplatin and doxorubicin in non-small cell lung cancer is inhibited by silencing of Hif-1alpha gene. Cancer Chemother Pharmacol2006, 58:776-784. 10.1007/s00280-006-0224-7
14. Skvortsova I, Skvortsov S, Haidenberger A, Devries A, Nevinny-Stickel M, Saurer M, et al.: Effects of paclitaxel and docetaxel on EGFR-expressing human carcinoma cells under normoxic versus hypoxic conditions in vitro. J Chemother2004, 16:372-380. 10.1179/joc.2004.16.4.372
15. Wohlkoenig C, Leithner K, Deutsch A, Hrzenjak A, Olschewski A, Olschewski H: Hypoxia-induced cisplatin resistance is reversible and growth rate independent in lung cancer cells. Cancer Lett2011, 308:134-143. 10.1016/j.canlet.2011.03.014
16. Florea AM, Buesselberg D: Cisplatin as an anti-tumor drug: cellular mechanisms of activity, drug resistance and induced side effects. Cancers2011, 3:1351-1371. 10.3390/cancers3011351
17. Ozkaya S, Findik S, Dirican A, Atici AG: Long-term survival rates of patients with stage IIIB and IV non-small cell lung cancer treated with cisplatin plus vinorelbine or gemcitabine. Exp Ther Med 2012, 4:1035-1038.
18. Swinson DE, Jones JL, Cox G, Richardson D, Harris AL, KJ O'B: Hypoxia-inducible factor-1 alpha in non-small cell lung cancer: relation to growth factor, protease and apoptosis pathways. Int J Cancer2004, 111:43-50. 10.1002/ijc.20052
19. Geng H, Harvey CT, Pittsenbarger J, Liu Q, Beer TM, Xue C, et al.: HDAC4 protein regulates HIF-1a protein lysine acetylation and cancer cell response to hypoxia. J Biol Chem2011, 286:38095-38102. 10.1074/jbc. M111.257055
20. Qian DZ, Kachhap SK, Collis SJ, Verheul HM, Carducci MA, Atadja P, et al.: Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1 alpha. Cancer Res2006, 66:8814-8821. 10.1158/0008-5472.CAN-05-4598
21. Atadja P: Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges. Cancer Lett2009, 280:233-241. 10.1016/j.canlet.2009.02.019
22. Ma YY, Iin H, Moh JS, Chen KD, Wang IW, Ou YC, et al.: Low-dose LBH589 increases the sensitivity of cisplatin to cisplatin-resistant ovarian cancer cells. Taiwan J Obstet Gynecol2011, 50:165-171. 10.1016/j.tjog.2011.01.022
23. Lemoine M, Derenzini E, Buglio D, Medeiros LJD RE, Zhang J, Ji Y, et al.: The pan-deacetylase inhibitor panobinostat induces cell death and synergizes with everolimus in Hodgkin lymphoma cell lines. Blood2012, 119:4017-4025. 10.1182/blood-2011-01-331421
24. Wang H, Cao Q, Dudek AZ: Phase II study of panobinostat and bortezomib in patients with pancreatic cancer progressing on gemcitabine-based therapy. Anticancer Res 2012, 32:1027-1031.
25. Crisanti MC, Wallace AF, Kapoor V, Vandermeers F, Dowling ML, Pereira LP, et al.: The HDAC inhibitor panobinostat (LBH589) inhibits mesothelioma and lung cancer cells in vitro and in vivo with particular efficacy for small cell lung cancer. Mol Cancer Ther 2009, 8:2221-2231.
26. Zhou Q, Agoston AT, Atadja P, Nelson WG, Davidson NE: Inhibition of histone deacetylases promotes ubiquitin-dependent proteasomal degradation of DNA methyltransferase 1 in human breast cancer cells. Mol Cancer Res2008, 6:873-883. 10.1158/1541-7786.MCR-07-0330
27. Kauh J, Fan S, Xia M, Yue P, Yang FR, Sun SY: c-FLIP degradation mediates sensitization of pancreatic cancer cells to TRAIL-induced apoptosis by the histone deacetylase inhibitor LBH589. PLoS ONE2010, 5:e10376. 10.1371/journal.pone.0010376
28. Berndtsson MH M, Panaretakis T, Havelka AM, Shoshan MC, Linder S: Acute apoptosis by cisplatin requires induction of reactive oxygen species but is not associated with damage to nuclear DNA. Int J Cancer2007, 120:175-180. 10.1002/ijc.22132
29. Michaels J, Vitale I, Galluzzi L, Adam J, Olaussen KA, Kepp O, et al.: Cisplatin resistance associated with PARP hyperactivation. Cancer Res2013, 73:2271-2280. 10.1158/0008-5472.CAN-12-3000
30. Bunn PA, Kelly K: New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. Clin Cancer Res 1998, 34:1087-1100.
31. Marek L, Hamacher A, Hansen F, Kuna K, Gohlke H, Kassack M, et al.: Histone Deacetylase (HDAC) Inhibitors with a Novel Connecting Unit Linker Region Reveal a Selectivity Profile for HDAC4 and HDAC5 with Improved Activity against Chemoresistant Cancer Cells. J Med Chem2013, 56:427-436. 10.1021/jm301254q
32. Okudela K, Mitsui H, Suzuki T, Woo T, Tateishi Y, Umeda S, et al.: Expression of HDAC9 in lung cancer - potential role in lung carcinogenesis. Int J Clin Exp Pathol 2014, 7:213-220.
33. Perez RP: Cellular and molecular determinants of cisplatin resistance. Eur J Cancer1998, 34:1535-1542. 10.1016/S0959-8049(98)00227-5
34. Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, et al.: Molecular mechanisms of cisplatin resistance. Oncogene2012, 31:1869-1883. 10.1038/onc.2011.384
35. Cea M, Cagnetta A, Gobbi M, Patrone F, Richardson PG, Hideshima T, et al.: New insights into the treatment of multiple myeloma with histone deacetylase inhibitors. Curr Pharm Des2013, 19:734-744. 10.2174/138161213804581945
36. Wagner JM, Hackanson B, Luebbert M, Jung M: Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy. Clin Epigenetics2010, 1:117-136. 10.1007/s13148-010-0012-4
37. Ocio EM, Vilanova D, Atadja P, Maiso P, Crusoe E, Fernandez-Lazaro D, et al.: In vitro and in vivo rationale for the triple combina-tion of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma. Haematologica2010, 95:794-803. 10.3324/haematol.2009.015495
38. Fiskus W, Rao R, Balusu R, Ganguly S, Tao J, Sotomayor E, et al.: Superior efficacy of a combined epigenetic therapy against human mantle cell lymphoma cells. Clin Cancer Res2012, 18:6227-6238. 10.1158/1078-0432.CCR-12-0873
39. Lee SC, Cheong HJ, Kim SJ, Yoon J, Kim HJ, Kim KH, et al.: Low-dose combinations of LBH589 and TRAIL can overcome TRAIL-resistance in colon cancer cell lines. Anticancer Res 2011, 31:3385-3394.
40. Sunaga N, Shames DS, Girard LP, Larsen JE M, Imai H, Soh J, et al.: Knockdown of oncogenic KRAS in non-small cell lung cancers suppresses tumor growth and sensitizes tumor cells to targeted therapy. Mol Cancer Ther2011, 10:336-346. 10.1158/1535-7163.MCT-10-0750
41. Richon VM, Sandhoff TW, Rifkind RA, Marks PA: Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci U S A2000, 97:10014-10019. 10.1073/pnas.180316197
42. Dempke W, Voigt W, Grothey A, Hill B, Schmoll HJ: Cisplatin resistance and oncogenes - a review. Anticancer Drugs2000, 11:225-236. 10.1097/00001813-200004000-00001
43. Sonnemann J, Marx C, Becker S, Wittig S, Palani CD, Kraemer OH, et al.: p53-dependent and ßp53-independent anticancer effects of different histone deacetylase inhibitors. Br J Cancer 2013, 110:656-667.
44. Burgess A, Ruefli A, Beamish H, Warrener R, Sunders N, Johnstone R, et al.: Histone deacetylase inhibitors specifically kill nonproliferating tumour cells. Oncogene2004, 23:6693-6701. 10.1038/sj.onc.1207893
45. Minucci S, Pelicci PG: Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer2006, 6:38-51. 10.1038/nrc1779
46. Prystowsky MB, Adomako A, Smith RV, Kawachi N, McKimpson W, Atadja P, et al.: The histone deacetylase inhibitor LBH589 inhibits expression of mitotic genes causing G2/M arrest and cell death in head and neck squamous cell carcinoma cell lines. J Pathol2009, 218:467-477. 10.1002/path.2554
47. Ozaki K, Kishikawa F, Tanaka M, Sakamoto T, Tanimura S, Kohno M: Histone deacetylase inhibitors enhance the chemosensitivity of tumor cells with cross-resistance to a wide range of DNA-damaging drugs. Cancer Sci2008, 99:376-384. 10.1111/j.1349-7006.2007.00669.x
48. Iida Y, Aoki K, Asakura T, Ueda K, Yanaihara N, KTkakura S, et al.: Hypoxia promotes glycogen synthesis and accumulation in human ovarian clear cell carcinoma. Int J Oncol 2012, 40:2122-2130.
49. Bohonowych JE, Peng S, Gopal U, Hance MW, Wing SB, Argraves KM, et al.: Comparative analysis of novel and conventional Hsp90 inhibitors on HIF activity and angiogenic potential in clear cell renal cell carcinoma: implications for clinical evaluation. BMC Cancer2011, 11:520. 10.1186/1471-2407-11-520
50. Stronach EA, Alfraidi AR N, Datler C, Studd JB, Agarwal R, Guney TG, et al.: HDAC4-regulated STAT1 activation mediates platinum resistance in ovarian cancer. Cancer Res2011, 71:4412-4422. 10.1158/0008-5472.CAN-10-4111
51. De Cecco L, Berardi M, Sommariva M, Cataldo A, Canevari SDM, Iorio MV, et al.: Increased sensitivity to chemotherapy induced by CpG-ODN treatment is mediated by microRNA modulation. PLoS ONE2013, 8:e58849. 10.1371/journal.pone.0058849
52. Greco WR, Bravo G, Persons JC: The search for synergy: a critical review from response surface perspective. Pharmacol Rev 1995, 47:331-385.